rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Butterfly Network, Inc.

BFLY · NYSE

Health CareMedical DevicesIn trendAI

BFLY stood above a rising 150-day average in 48 of the last 52 weekly readings, including each of the last 48 weeks. It is 2.1% above that average now. Medical Devices: 29% of its 181 stocks in an uptrend (−2 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
48 in a row
Industry in uptrend
29% -2 in 4 wk
Insider buys, 12 months
$14.1M
Insider sales, 12 months
$235.6M
Officials’ trades on record
0
Institutions holding
235 (+8)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 48 of 52 weeks.

23 Apr – 22 Oct
18%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$139.3M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months9
Sale orders, 12 months65
Buyers · sellers2 · 9
WhoDidSharesTraded
Joseph DevivoPresident & CEOsold35,790at $10.026 Oct 2026filed 8 Oct 2026
Megan CarlsonCAO and SVP, Financesold10,114at $8.752 Oct 2026filed 6 Oct 2026
Joseph DevivoPresident & CEOsold3,169at $10.0223 Sep 2026filed 24 Sep 2026
Joseph DevivoPresident & CEOsold2,811at $10.0022 Sep 2026filed 24 Sep 2026
Megan CarlsonCAO and SVP, Financesold13,804at $7.304 Sep 2026filed 9 Sep 2026
Steve CashmanChief Business Officersold140,112at $7.304 Sep 2026filed 9 Sep 2026
Nicholas CaezzaDeputy General Counselsold1,709at $8.152 Sep 2026filed 4 Sep 2026
Larry RobbinsDirectorsold582,500at $8.9717 Aug 2026filed 17 Aug 2026
Larry RobbinsDirectorsold824,700at $8.7014 Aug 2026filed 17 Aug 2026
S. Louise PhanstielDirectorbought115,200at $8.6814 Aug 2026filed 17 Aug 2026
Larry RobbinsDirectorsold215,233at $9.5413 Aug 2026filed 17 Aug 2026
Larry RobbinsDirectorsold500,000at $9.2413 Aug 2026filed 17 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders235+8 on the quarter
New · exited47 · 40
Reported value$1.3B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202618,821,463$158.5M+2,859,983+17.9%
GLENVIEW CAPITAL MANAGEMENT, LLCunchanged · filed 14 Aug 202614,335,055$120.7M00.0%
Hood River Capital Management LLCadded · filed 14 Aug 202613,190,130$111.1M+4,569,282+53.0%
Fosun International Ltdreduced · filed 12 Aug 202610,234,923$86.2M-481,707−4.5%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20268,559,346$72.1M+367,227+4.5%
D. E. Shaw & Co., Inc.added · filed 14 Aug 20266,392,827$53.8M+5,272,536+470.6%
STATE STREET CORPadded · filed 7 Aug 20265,762,672$48.5M+223,012+4.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20265,345,672$45.0M+536,568+11.2%
ARK Investment Management LLCreduced · filed 14 Aug 20265,085,456$42.8M-142,047−2.7%
Nuveen, LLCadded · filed 11 Aug 20265,056,372$42.6M+1,306,436+34.8%
31 Mar 2023 – 30 Jun 2026
141187232Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Michael Noonen Company insiderDirector · last 13 Oct 20260 · 0
Joseph Devivo Company insiderPresident & CEO · last 6 Oct 20262 · 9
Megan Carlson Company insiderCAO and SVP, Finance · last 2 Oct 20260 · 7
Steve Cashman Company insiderChief Business Officer · last 4 Sep 20261 · 9
Nicholas Caezza Company insiderDeputy General Counsel · last 2 Sep 20260 · 7
Larry Robbins Company insiderDirector · last 17 Aug 202613 · 5
S. Louise Phanstiel Company insiderDirector · last 14 Aug 20262 · 1
Jonathan M. Rothberg Company insiderDirector · last 22 Jul 20260 · 27
John N. Doherty Company insiderEVP, CFO · last 20 Jul 20260 · 3
Victor Ku Company insiderChief Technology Officer · last 20 Jul 20260 · 3
Caroll H. Neubauer Company insiderDirector · last 22 Jun 20260 · 0
Elazer R. Edelman Company insiderDirector · last 22 Jun 20260 · 0

Same industry

RCEL Avita MedicalLeading+127%
HTFL HeartflowLeading+57%
ATRC AtriCureLeading+54%
HAE HaemoneticsLeading+43%
BVS BioventusLeading+31%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202546.9%
Operating profit marginFY 2025 · to 31 Dec 2025-88.5%
Free cash flow marginFY 2025 · to 31 Dec 2025-16.4%
Return on capital employedFY 2025 · to 31 Dec 2025-37.3%
Research spendFY 2025 · to 31 Dec 202537.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$150.5M
Free cash flowFY 2025 · to 31 Dec 2025−$16.0M

Analyst forecasts

No analyst forecasts yet.